The 2014 EAU Guidelines on Renal Cell Carcinoma (RCC) provide an updated, evidence-based management framework for RCC. The guidelines were developed by a multidisciplinary panel using standardized, transparent, and reproducible methods. Key topics included percutaneous biopsy of renal masses, treatment of localized RCC, lymph node dissection, management of venous thrombus, systemic therapy, and local treatment of metastases. Systematic reviews adhering to PRISMA guidelines were conducted, with a focus on randomized controlled trials (RCTs) and other high-quality studies. The evidence synthesis revealed that most studies were retrospective, but for systemic treatment of metastatic RCC, several RCTs provided higher-level evidence. The guidelines emphasize the importance of risk stratification, with recommendations based on tumor stage, grade, and molecular factors. For localized RCC, partial nephrectomy is preferred over radical nephrectomy when feasible, with laparoscopic techniques showing lower morbidity. For metastatic RCC, cytoreductive nephrectomy combined with systemic therapy is recommended for patients with good performance status. Systemic therapy options include targeted agents like sunitinib, pazopanib, and everolimus, with recommendations based on risk stratification. The guidelines also address the management of venous tumor thrombus, with surgical resection being the standard approach. Surveillance strategies are tailored to risk levels, with intensified follow-up for high-risk patients. The guidelines aim to improve clinical decision-making and patient outcomes through evidence-based recommendations.The 2014 EAU Guidelines on Renal Cell Carcinoma (RCC) provide an updated, evidence-based management framework for RCC. The guidelines were developed by a multidisciplinary panel using standardized, transparent, and reproducible methods. Key topics included percutaneous biopsy of renal masses, treatment of localized RCC, lymph node dissection, management of venous thrombus, systemic therapy, and local treatment of metastases. Systematic reviews adhering to PRISMA guidelines were conducted, with a focus on randomized controlled trials (RCTs) and other high-quality studies. The evidence synthesis revealed that most studies were retrospective, but for systemic treatment of metastatic RCC, several RCTs provided higher-level evidence. The guidelines emphasize the importance of risk stratification, with recommendations based on tumor stage, grade, and molecular factors. For localized RCC, partial nephrectomy is preferred over radical nephrectomy when feasible, with laparoscopic techniques showing lower morbidity. For metastatic RCC, cytoreductive nephrectomy combined with systemic therapy is recommended for patients with good performance status. Systemic therapy options include targeted agents like sunitinib, pazopanib, and everolimus, with recommendations based on risk stratification. The guidelines also address the management of venous tumor thrombus, with surgical resection being the standard approach. Surveillance strategies are tailored to risk levels, with intensified follow-up for high-risk patients. The guidelines aim to improve clinical decision-making and patient outcomes through evidence-based recommendations.